全文获取类型
收费全文 | 6998篇 |
免费 | 482篇 |
国内免费 | 20篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 238篇 |
妇产科学 | 157篇 |
基础医学 | 1184篇 |
口腔科学 | 92篇 |
临床医学 | 688篇 |
内科学 | 1353篇 |
皮肤病学 | 174篇 |
神经病学 | 670篇 |
特种医学 | 161篇 |
外国民族医学 | 1篇 |
外科学 | 836篇 |
综合类 | 101篇 |
一般理论 | 2篇 |
预防医学 | 672篇 |
眼科学 | 115篇 |
药学 | 416篇 |
中国医学 | 35篇 |
肿瘤学 | 560篇 |
出版年
2023年 | 34篇 |
2022年 | 61篇 |
2021年 | 129篇 |
2020年 | 93篇 |
2019年 | 124篇 |
2018年 | 143篇 |
2017年 | 118篇 |
2016年 | 131篇 |
2015年 | 165篇 |
2014年 | 191篇 |
2013年 | 272篇 |
2012年 | 465篇 |
2011年 | 450篇 |
2010年 | 257篇 |
2009年 | 269篇 |
2008年 | 432篇 |
2007年 | 455篇 |
2006年 | 510篇 |
2005年 | 439篇 |
2004年 | 439篇 |
2003年 | 397篇 |
2002年 | 389篇 |
2001年 | 139篇 |
2000年 | 108篇 |
1999年 | 89篇 |
1998年 | 103篇 |
1997年 | 81篇 |
1996年 | 72篇 |
1995年 | 80篇 |
1994年 | 49篇 |
1993年 | 58篇 |
1992年 | 41篇 |
1991年 | 48篇 |
1990年 | 47篇 |
1989年 | 36篇 |
1988年 | 35篇 |
1987年 | 33篇 |
1986年 | 46篇 |
1985年 | 49篇 |
1984年 | 32篇 |
1983年 | 38篇 |
1982年 | 26篇 |
1981年 | 21篇 |
1980年 | 28篇 |
1979年 | 26篇 |
1978年 | 21篇 |
1976年 | 13篇 |
1975年 | 14篇 |
1974年 | 21篇 |
1973年 | 18篇 |
排序方式: 共有7500条查询结果,搜索用时 31 毫秒
1.
Cromb Amandine Le Loarer Franois Sitbon Maxime Italiano Antoine Stoeckle Eberhard Buy Xavier Kind Michle 《European radiology》2020,30(5):2413-2424
European Radiology - The strongest adverse prognostic factor in myxoid/round cell liposarcomas (MRC-LPS) is the presence of a round cell component above 5% within the tumor bulk. Its identification... 相似文献
2.
3.
4.
5.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
6.
7.
8.
Laurence Dorne Nadir Alikacem Robert Guidoin Michle Auger 《Magnetic resonance in medicine》1995,34(4):548-554
We have used 29Si solid-state nuclear magnetic resonance (NMR) spectroscopy to study the chemical structure of the silicone gels in virgin and explanted breast prostheses. Despite evidences of alteration in the morphological appearance of the silicone gel inside the breast prosthesis, our results do not reveal changes in the chemical nature and structure of the silicone gels after implantation. In addition to the main 29Si resonance peak at ?22.26 ppm that corresponds to the resonance frequency of the D repeat unit of the polysiloxane chains, the high sensitivity of our NMR technique allows the detection of very low concentrations of silicone compounds. Within our experimental detection limit of 0.2%, no signal between ?90 ppm and ?150 ppm are observed. This indicates that no silica products are present inside the gel of the prostheses. Furthermore, our 29Si NMR spectra indicate differences in the chemical compositions of the silicone gels from different manufacturers. 相似文献
9.
Margaretha Jennerwein Ronald Gust Richard Müller Helmut Schnenberger Jürgen Engel Martin R. Berger Dietrich Schmhl Siegfried Seeber Reinhanidt Osieka Ghanem Atassi Danile Marchal-De Bock 《Archiv der Pharmazie》1989,322(2):67-73
The activity of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine] dichloroplatinum(II)-complexes (1-PtCl2,R,S; 2-PtCl2, R,R/S,S; 3-PtCl2, R,R; 4-PtCl2, S,S) on several tumor models (MDA-MB 231 breast cancer cell line; P 388 leukemia, mouse; L 1210 leukemia, mouse; L 5222 leukemia, rat; Ehrlich ascites tumor, mouse--wildtype; cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.) is described. For comparison the analogous [1,2-bis(4-hydroxyphenyl)ethylendiamine]dichloroplatinum (II)-complexes (5-PtCl2, R, S; 6-PtCl2, R,R/S,S; 7-PtCl2, R,R; 8-PtCl2, S,S) and cisplatin are used. 1-PtCl2 to 4-PtCl2 (OH in 3,3'-positions) show their maximum antitumor effect at lower doses than 5-PtCl2 to 8-PtCl2 (OH in 4,4'-positions). 2-PtCl2 and 6-PtCl2 (R,R/S,S) are more active than 1-PtCl2 and 5-PtCl2 (R,S). 4-PtCl2 and 8-PtCl2 (S,S) are superior to 3-PtCl2 and 7-PtCl2 (R,R). On the L 5222 leukemia 2-PtCl2 (R,R/S,S), 4-PtCl2 (S,S) and 8-PtCl2 (S,S) markedly surpass cisplatin. Strong effects are produced by 2-PtCl2 to 4-PtCl2 on the Ehrlich ascites tumor (wildtype, cisplatin-, etoposide-, cyclophosphamide-, and daunomycin-resistant, resp.). The combination of 4-PtCl2 with cisplatin results in a weakly synergistic effect. 相似文献
10.
R J Ligthelm U Mouritzen H Lynggaard M Landin-Olsson C Fox C le Devehat E Romero A Liebl 《Experimental and clinical endocrinology & diabetes》2006,114(9):511-519
AIMS: To show that a thrice daily meal-time biphasic insulin aspart (BIAsp) treatment regimen is as efficacious as a 4 times daily basal-bolus regimen with human isophane insulin (NPH) and insulin aspart (IAsp). METHODS: A multinational, randomised, open-label parallel-group trial in 394 patients with type 2 diabetes on a once or twice daily insulin regimen. Patients were randomised 1:1 to BIAsp or IAsp+NPH for 16 weeks. The BIAsp group was treated according to individual needs using BMI as a surrogate index of insulin resistance. Subjects administered BIAsp 70 (BMI< or =30 kg/m (2)) or BIAsp 50 (BMI>30 kg/m (2)) with breakfast and lunch and BIAsp 30 with dinner. The IAsp+NPH group injected IAsp at meals and NPH at bedtime as basal insulin. HbAlc levels after 16 weeks were compared between treatments using a predefined non-inferiority criterion of 0.4%. The incidence of hypoglycaemic episodes and adverse events was evaluated. RESULTS: Mean HbAlc (+/-SD) decreased from 9.1+/-0.7% to 7.8+/-1.0% with both treatments. Glycaemic control provided by BIAsp was non-inferior to that obtained by the IAsp+NPH (intention to treat ITT) population: diff, HbAlc -0.05%; 95% CI (-0.24; 0.14); per protocol (PP) population: diff, HbAlc -0.03%; 95% CI (-0.23; 0.16). Similar improvements in glycaemic control in both groups were confirmed by self-measured 8-point plasma glucose (PG) profiles, average and fasting PG concentrations, and average prandial PG increments. The incidence of adverse events and hypoglycaemic episodes was similar in the two treatment groups. CONCLUSIONS: A thrice daily meal-time BIAsp regimen is a suitable alternative to an intensified insulin regimen in people with inadequately controlled type 2 diabetes mellitus, and requires fewer daily injections than a basal-bolus therapy without compromising efficacy and safety. 相似文献